JHJohan L. K. Van Hove

Johan L. K. Van Hove

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Johan L. K. Van Hove has a total of 419 co-authors. Here are the top co-authors by number of shared publications:

  • Marisa W. Friederich

    Department of Pediatrics, Section of Clinical Genetics and Metabolism University of Colorado School of Medicine Aurora Colorado USA

    14 shared publications
  • Michael A. Swanson

    Department of Pediatrics, Section of Clinical Genetics and Metabolism University of Colorado Anschutz Medical Campus Aurora Colorado USA

    7 shared publications
  • Austin A. Larson

    Department of Pediatrics, Section of Clinical Genetics and Metabolism, University of Colorado, Aurora, CO, USA

    6 shared publications
  • Curtis R. Coughlin

    Section of Clinical Genetics and Metabolism, Department of Pediatrics University of Colorado Anschutz Medical Campus Aurora Colorado USA

    6 shared publications
  • Curtis R. Coughlin

    Department of Pediatrics Section of Clinical Genetics and Metabolism, University of Colorado School of Medicine Aurora Colorado USA

    5 shared publications
  • Emily Shelkowitz

    Department of Pediatrics, University of Washington, Seattle, USA

    5 shared publications

Latest Publications

  • Pyrophosphatase 2 Deficiency: Clinical Presentation, Diagnosis and Management

    by Hayley Nehoff, Ian Crozier, Hilary Vernon, Christine James, Ana I. Fernández-Ávila, Michael Bowes, Esther Gomez-Gonzalez, Colin Phoon, Kristy DiLoreto, Martin E. Matsumura, et al.

    BACKGROUND: PPA2 (pyrophosphatase 2) deficiency is a relatively newly recognized condition caused by biallelic variants in the PPA2 gene. The gene encodes the mitochondrial enzyme PPA2, involved in the production of orthophosphate in the mitochondrial matrix. Affected individuals typically present with sudden cardiac death or acute heart failure following common viral illnesses in infants and toddlers, or following exposure to small amounts of alcohol as teenagers. The condition has a high mortality rate in these situations. Here, we explore the clinical presentations and current management of these patients with a view to guiding future emergency clinical management of cases. METHODS: Case records from published and unpublished affected individuals diagnosed with PPA2 deficiency were compiled in a retrospective cohort study of genotypes, phenotypes and clinical management protocols in individuals with biallelic (likely) pathogenic PPA2 variants. RESULTS: We collated 93 affected individuals from 53 families, 14 of which have not previously been reported. Patient presentation is invariably acute, often associated with fatigue, vomiting, seizures and collapse. Generally, presenting individuals received standard emergency management with cardiopulmonary resuscitation and appropriate management of arrhythmia, and here we present compiled clinical management protocols for emergency and ongoing treatment of PPA2-deficient patients. A pronounced inheritance rate of pathogenic alleles from carrier parents is noted, and further research is warranted to confirm and investigate any selective advantage for gametes carrying pathogenic PPA2 variants. CONCLUSIONS: PPA2 deficiency has a high mortality rate following exposure to common childhood viruses in children around and under the age of 3 and in teenagers exposed to ethanol. We have presented current therapeutic approaches gathered from a worldwide survey of clinicians treating their patients, possible pathogenic mechanisms and inheritance peculiarities of the condition and provide a comprehensive review of the current recommendations surrounding patients’ clinical management.

  • Open Access

    Comprehensive functional testing in fibroblasts has strong utility to diagnose mitochondrial disease

    by Johan L K Van Hove, Marisa W Friederich, Roxanne A Van Hove, Jessica C Lee, Kaz M Knight, Tonia E Donovan, Lori Silveira, Rebecca D Ganetzky, Michio Hirano, Jose Abdenur, et al.

    Genome sequencing is the first-line diagnostic method for primary mitochondrial diseases (PMDs), yet its effectiveness is limited by variants of uncertain significance or unresolved genetic findings. We systematically evaluated the clinical performance of fibroblast-based functional testing, comprised of respiratory chain enzyme assays, blue native polyacrylamide gel electrophoresis with in-gel activity staining (BN-PAGE), complex I assembly assay, and targeted protein abundance assessments, in a cohort of 204 genetically confirmed PMD patients, 51 healthy controls, and 53 patients with differential diagnoses. Individually, enzyme assays, BN-PAGE, and complex I assembly assay showed sensitivities of 46%, 40%, and 49%, with specificities of 93%, 98%, and 99%, respectively. Combined, the assays achieved an overall sensitivity of 76%, a specificity 93%, a positive predictive value 96%, and a negative predictive value of 67%. Sensitivity was highest for isolated respiratory chain deficiencies, nuclear DNA-encoded mitochondrial translation defects, cofactor deficiencies, and mitochondrial aminoacyl-tRNA synthetase disorders, whereas mitochondrial DNA variants and maintenance defects remained challenging. Secondary mitochondrial dysfunction was rare. The strong clinical utility of comprehensive fibroblast functional testing improves PMD diagnosis when used complementary to genomic sequencing.


  • Delineation and Phenotypic Expansion of TOP3A ‐Related Mitochondrial Disease in Childhood

    by Rodrigo T. Starosta, Marisa W. Friederich, Graeme Preston, Lily Walson, Julie Hong Yin, Steven Lang, Hanna J. Tadros, Yue Wang, Elizabeth Mizerik, David Mirsky, et al.

    TOP3A ‐related mitochondrial disease is a rare autosomal recessive primary mitochondrial cytopathy caused by loss‐of‐function of the mitochondrial‐specific isoform of topoisomerase 3α, leading to multiple mitochondrial DNA deletions and mitochondrial DNA depletion. This condition has been associated with two different phenotypes. Very young patients present with severe growth faltering and early mortality, that is consistent with a Bloom syndrome‐like disorder. Adult‐onset chronic progressive external ophthalmoplegia, myopathy, and sensory ataxia, with rare hypertrophic cardiomyopathy (a MIRAS‐like phenotype), reflects a mitochondrial disorder. In this article, we expand the phenotype spectrum of TOP3A ‐related mitochondrial disease with a mitochondrial childhood onset form and present four previously unreported patients, including the outcomes of heart transplantation for three patients. Histopathological, electron microscopical, biochemical, and molecular characterization of muscle and heart tissue indicated mitochondrial dysfunction with combined complex deficiency associated with a mitochondrial DNA maintenance disorder primarily expressed in the heart. Heart transplantation was successful in patients with TOP3A ‐related mitochondrial disease that presented with cardiomyopathy in childhood, although there is slowly progressive neurological disease. In childhood, TOP3A ‐related disease presents with a combination of developmental delays, sensorineural hearing loss, cardiomyopathy with rhythm abnormalities, stroke‐like episodes, and Leigh‐like phenotype, and, in some, epilepsy. These mitochondrial phenotypes are different from the infantile Bloom‐like syndrome and the adult‐onset form.

  • Open Access

    The clinical utility of functional testing in fibroblasts to diagnose primary mitochondrial disease

    by Johan L.K. Van Hove, Marisa W. Friederich, Roxanne A. Van Hove, Jessica C. Lee, Kaz M. Knight, Tonia E. Donovan, Lori Silveira, Rebecca D. Ganetzky, Michio Hirano, Jose Abdenur, et al.

    Genome sequencing of the heterogeneous primary mitochondrial disorders (PMD) frequently reveals variants of uncertain significance that require functional tests for diagnosis, and does not identify variants in all patients. We analyzed mitochondrial enzyme assays, blue native polyacrylamide gel electrophoresis (BN-PAGE) with in-gel activity staining, complex I assembly blot, and select protein abundances in fibroblasts of a case series of 204 PMD patients divided into functional classes, in comparison to 51 controls and 53 differential diagnostic conditions. Overall, sensitivity and specificity for respiratory chain enzyme assays were 46% and 93% respectively, for BN-PAGE 40% and 98%, for complex I assembly assay 49% and 99%. The overall sensitivity of all tests was 76%, specificity 93%, with positive predictive value 96% and negative predictive value 67%. Categories with high sensitivity were isolated complex deficiencies, nuclear DNA-encoded mitochondrial protein synthesis defects, co-factor defects, and mitochondrial amino-acyl-tRNA synthetase conditions when aided by protein abundance. Mitochondrial DNA mutations and maintenance disorders showed poor sensitivities. Secondary dysfunctions were rare. A complete battery of functional tests showed strong diagnostic clinical utility in fibroblasts. One sentence summary: A combination of four mitochondrial functional tests to identify or confirm suspected primary mitochondrial disease in fibroblasts had good sensitivity and excellent specificity, well beyond what was perceived using enzyme assays only.


  • Open Access

    A Nonketotic Hyperglycinemia Mouse Shows Wide‐Ranging Biochemical Consequences of Elevated Glycine, Reduced Folate One‐Carbon Charging, and Serine Deficiency

    by Michael A. Swanson, Hua Jiang, Lakshmi Divya Kolora, Rachel Molino, Richard Reisdorph, Cole R. Michel, Katrina A. Doenges, Kit‐Yi Leung, Xiangping Lin, Frank Wong, et al.

    Nonketotic hyperglycinemia is a severe neonatal epileptic encephalopathy caused by deficient glycine cleavage enzyme activity, for which currently no effective treatment exists. Incomplete understanding of brain biochemistry represents a major knowledge gap to develop new treatments. We examined the biochemistry in blood, liver, cortex, hippocampus, and cerebellum of a mouse model homozygous for the Gldc variant p.Ala394Val. Glycine was increased in all compartments and caused increased brain neurotoxic metabolites guanidinoacetate and methylglyoxal, and also N‐acetylglycine and cystathionine. The glycine extruding transporter Slc6a20 was increased. There was reduced one‐carbon folate charging with secondarily reduced methionine in the cortex, and reduced alternative one‐carbon donors L‐serine and formate. Serine deficiency was associated with reduced amounts of sphingosine, sphingomyelin, and ceramide species important for myelination, but not phosphatidylserines. There was a region‐specific deficiency of D‐serine in the cortex and hippocampus. This difference, also present in humans, was strain‐ and age‐related, most evident in young J129X1/SvJ mice, reflecting symptomatology. There was no evidence of oxidative stress or a bioenergetic defect. The biochemistry of the nonketotic hyperglycinemia mouse model can be traced to three components: increased glycine, reduced folate one‐carbon charging, and decreased L‐ and D‐serine. These changes will need to be addressed in new therapeutic approaches.


  • The History and Nosology of the Glycine Disorders: A Framework for Clinicians

    by Arthavan Selvanathan, Ashley Hertzog, Curtis R. Coughlin, Michael A. Swanson, Johan L. K. Van Hove

    Despite its simple chemical structure, glycine plays a complex role in the body. The glycine cleavage system regulates brain glycine levels and is a key one‐carbon donor to folate. Its metabolism is tightly integrated with that of serine. In addition to its biochemical role, glycine functions as a neurotransmitter and neuromodulator. Primary defects in the glycine cleavage system have long been known to cause human disease with a primarily neurological phenotype, and this was labelled as ‘nonketotic hyperglycinaemia’ in 1968. With increasing availability of molecular testing, many additional genetic conditions became apparent, as well as non‐genetic factors that cause hyperglycinaemia. There is now a much greater appreciation of the marked clinical impact of this heterogeneity. The previous terminology of ‘classical’ and ‘atypical’ nonketotic hyperglycinaemia does not adequately address these numerous genetic aetiologies, nor does it account for the phenotypic spectrum within individual genetic disorders. We provide here a clinically relevant classification of the glycine encephalopathies, based on the underlying genetic aetiology and its relation to the glycine cleavage system. Characteristic clinical and biochemical features of each condition, as well as non‐genetic phenocopies that cause hyperglycinaemia, are discussed in detail. This provides a readily usable framework for clinicians when faced with a patient with elevated glycine levels.


  • Open Access

    Dominant negative ATP5F1A variants disrupt oxidative phosphorylation causing neurological disorders

    by Sara M Fielder, Marisa W Friederich, Daniella H Hock, Jessie R Zhang, Liana M Valin, Jill A Rosenfeld, Kevin T A Booth, Natasha J Brown, Rocio Rius, Tanavi Sharma, et al.

    ATP5F1A encodes the α-subunit of complex V of the respiratory chain, which is responsible for mitochondrial ATP synthesis. We describe 6 probands with heterozygous de novo missense ATP5F1A variants that presented with developmental delay, intellectual disability, and movement disorders. All variants were located at the contact points between the α- and β-subunits. Functional studies in C. elegans revealed that the variants were damaging via a dominant negative genetic mechanism. Biochemical and proteomics studies of proband-derived cells showed a marked reduction in complex V abundance and activity. Mitochondrial physiology studies revealed increased oxygen consumption, yet decreased mitochondrial membrane potential and ATP levels indicative of uncoupled oxidative phosphorylation as a pathophysiologic mechanism. Our findings contrast with the previously reported ATP5F1A variant, p.Arg207His, indicating a different pathological mechanism. This study expands the phenotypic and genotypic spectrum of ATP5F1A -associated conditions and highlights how functional studies can provide an understanding of the genetic, molecular, and cellular mechanisms of ATP5F1A variants of uncertain significance. With 12 heterozygous individuals now reported, ATP5F1A is the most frequent nuclear genome cause of complex V deficiency.


  • In memoriam: Stephen G. Kahler, MD

    by Johan L.K. Van Hove, Priya S. Kishnani, David S. Millington, Dietrich Matern, Ayesha Ahmad

  • Open Access

    Dominant negative ATP5F1A variants disrupt oxidative phosphorylation causing neurological disorders

    by Sara M. Fielder, Marisa W. Friederich, Daniella H. Hock, Jessie R. Zhang, Liana M. Valin, Jill A. Rosenfeld, Kevin T.A. Booth, Natasha J. Brown, Rocio Rius, Tanavi Sharma, et al.

    ATP5F1A encodes the α-subunit of complex V of the respiratory chain, which is responsible for mitochondrial ATP synthesis. We describe 6 probands with heterozygous de novo missense ATP5F1A variants that presented with developmental delay, intellectual disability, and movement disorders. Functional evaluation in C. elegans revealed that all variants tested were damaging to gene function via a dominant negative genetic mechanism. Biochemical and proteomics studies showed a marked reduction in complex V abundance and activity in proband-derived blood cells and fibroblasts. Mitochondrial physiology studies in fibroblasts revealed increased oxygen consumption, yet decreased mitochondrial membrane potential and ATP levels indicative of uncoupled oxidative phosphorylation as a pathophysiologic mechanism. Our findings contrast functionally and clinically with the previously reported ATP5F1A variant, p.Arg207His, suggesting a distinct pathological mechanism. This study therefore expands the phenotypic and genotypic spectrum of ATP5F1A -associated conditions and highlights how functional studies can provide understanding of the genetic, molecular, and cellular mechanisms of ATP5F1A variants of uncertain significance. With 12 heterozygous individuals now reported, ATP5F1A is the most frequent nuclear genome cause of complex V deficiency.


  • The clinical utility in hospital‐wide use of growth differentiation factor 15 as a biomarker for mitochondrial DNA‐related disorders

    by Andrea Cortés Fernández, Jane Estrella, Devin Oglesbee, Austin A. Larson, Johan L.K. Van Hove

    Clinical recognition of primary mitochondrial disorders (PMD) is difficult due to the clinical and genetic heterogeneity. Whereas lactate has low sensitivity and specificity, in structured clinical studies growth differentiation factor 15 (GDF15) has shown promise with elevations in mitochondrial DNA (mtDNA)‐related PMD, but its specificity has been questioned. In a tertiary care hospital‐wide study, medical records were retrospectively reviewed from 418 cases where GDF15 levels were obtained by clinicians. Patients were classified into patients with PMD due to mtDNA‐related defects (mtDNA maintenance, mtDNA deletions, and mtDNA‐encoded tRNA variants), PMD due to structural defects or other nuclear causes, and in non‐mitochondrial disease. Patients with liver disease or systemic critical illness were excluded. GDF15 was assayed in a clinical laboratory with a cutoff of 750 ng/L. There were 38 mtDNA‐related PMD (GDF15 >750 pg/mL in 76%), 35 other nuclear DNA‐encoded PMD or structural subunits (31% elevated GDF15), 309 non‐mitochondrial disorders (13% elevated GDF15). Based on the highest Youden J‐index, the optimal cut‐off value to identify these target mtDNA‐related disorders was 815 pg/mL, with sensitivity 76%, specificity 88%, positive predictive value of 41% and negative predictive value of 97%. At this optimized cutoff level, mtDNA‐encoded PMD patients had elevated GDF15 in 76%, nuclear DNA‐encoded PMD in 26%, and non‐mitochondrial disorders in 11% of patients. Thus, in a real‐life clinical setting, after excluding abnormal liver function and critical illness, GDF15 had good clinical utility increasing the odds at predicting mtDNA‐related primary mitochondrial disorders 14‐fold, but not for structural or other nuclear‐encoded primary mitochondrial disorders.